CABRINI’S COVID-19 RESPONSE
We currently have precautionary measures in place to protect our patients and staff. Read more

Most of the treatments, devices, or interventions we rely on today are a direct result of clinical trials – they are essential to making improvements in healthcare.

At Cabrini, we offer a broad range of clinical trials giving patients access to new treatments or interventions long before they are available to the general public. Patients on clinical trials receive the best standard of care delivered by our highly trained medical staff.

Search for a clinical trial below or ask your healthcare provider about clinical trials suitable for you at Cabrini.

At Cabrini, we offer a wide range of clinical trials studying new ways to prevent, diagnose, or treat conditions and diseases. Clinical trials are key in helping us to provide you with the best possible care across your health journey.

Thinking of entering a clinical trial 

We recommend you learn and understand more about the essential facts, benefits and risks by visiting the Better Health Channel Clinical Trials website. In Australia, the regulations governing clinical trials make the process as safe as possible for clinical trial participants.

Patient safety

Patient safety is our key concern at Cabrini. Visit our ethics and research governance page to see how we are ensuring patient safety and how you can get in contact to lodge a complaint regarding a clinical trial.


Contact us

Oncology clinical trials
Micheleine Uhe, Team Manager Oncology Trials
P: (03) 9508 3481
E: muhe@cabrini.com.au

Cancer exercise clinical trials
Kelcey Bland, Cancer Exercise Laboratory
E: kbland@cabrini.com.au

All trials and general enquiries
Emma Baker, Director of Research
P: 0419 593 889
E: ebaker@cabrini.com.au

Clinicians internally and externally can refer patients to clinical trials at Cabrini. We accept referrals from across Victoria and Australia. As a private hospital, many of our clinical trial patients hold private health insurance—however, we are open to seeking eligibility for Medicare only patients. Please get in contact with us to discuss options for your patient and the role you can play in their trial.

Oncology clinical trials
Micheleine Uhe, Team Manager Oncology Trials
P: (03) 9508 3481
E: muhe@cabrini.com.au

Cancer exercise clinical trials
Kelcey Bland, Cancer Exercise Laboratory
E: kbland@cabrini.com.au

All trials and general enquiries
Emma Baker, Director of Research
P: 0419 593 889
E: ebaker@cabrini.com.au

Cabrini Research has resources available to undertake clinical trials at Cabrini as a lead investigator. Visit our research with us page to understand what we can assist with.

Cabrini is engaged in a large clinical trials program spanning multiple diseases and complications. We champion clinical trials to ensure our patients receive the latest developments in evidence based treatment available. Oncology (haematology and medical oncology) clinical trials program is the largest sponsor driven portfolio at Cabrini. Much of the information below is directed at sponsorship of the oncology trials, however, we welcome enquiries in all areas.

Oncology clinical trials – feasibility, startup, staffing
Micheleine Uhe, Team Manager Oncology Trials
P: (03) 9508 3481
E: muhe@cabrini.com.au

Oncology clinical trials – budgets, contracts
Rochelle Woods, Business Manager Oncology Trials
P: (03) 9508 3437
E: rwoods@cabrini.com.au

Cancer exercise clinical trials
Kelcey Bland, Cancer Exercise Laboratory
E: kbland@cabrini.com.au

All trials and general enquiries
Emma Baker, Director of Research
P: 0419 593 889
E: ebaker@cabrini.com.au

Protocol Number: COALITION

A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor

Protocol Number - OCEANIC AF

A multicenter, international, randomized, active comparator-controlled, double-blind, doubledummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke

Protocol Number - COVID-19 In Cancer Patients

A multi-centre national study of COVID-19 infection in cancer patients.

Download more information

Protocol Number - ACE

ACE Trial: Advanced Cancer and Cachexia Exercise Trial

Download more information